25-羟基维生素D3在50~60岁绝经后女性骨折中的变化

Abstract
Figure/Table
References (27)
Related Citation (3)

Download: PDF (575 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract [Abstract] Objective To investigate the changes of bone metabolism markers in postmenopausal women between 50 and 60 years of age with fractures. Methods From July 2014 to June 2015, in Shanghai Pudong New Area Gongli Hospital, 60 postmenopausal women between 50 and 60 years old [average age was (56.7±3.3) years] with fractures treated in were selected. The patients were divided into two groups by years after postmenopause, including 30 cases of 0-5 years (average: 54.5±3.3) after postmenopause, 30 cases of 5-10 years [average age was (58.8±0.9) years] after postmenopause. All the patients were measured height, weight, and bone metabolism markers, including 25 hydroxy vitamin D3 [25-(OH)D3], bone isoenzyme of alkaline phosphatase (BALP), Osteocalcin (OC), C-terminal crosslinking telopeptides of type Ⅰ collagen (u-NTX), type Ⅰ procollagen carboxy-terminal peptide (PICP) and N-terminal crosslinking telopeptides of type Ⅰ collagen (s-CTX). The differences in general and bone metabolism between the two groups were analyzed. Results Serum levels of 25-(OH)D3 in 5-10 years after postmenopause group decreased significantly compared with 0-5 years after postmenopause group, the differences were statistically significant (P < 0.05). There was no significant difference in serum BALP, OC, s-CTX, PICP, and u-NTX between 0-5 years postmenopause group and 5-10 years after postmenopause group, the differences were not statistically significant (P > 0.05). Conclusion Serum levels of 25-(OH)D3 decreased while the years after postmenopause increased. Postmenopausal women between 50 and 60 years old should promptly add vitamin D3 in order to prevent and delay the onset of fracture in postmenopausal women between 50 and 60 years old.

Key words： [Key words] Postmenopausal women Fracture Bone metabolism markers 25 hydroxy vitamin D3

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	KONG Dece1 YANG Tieyi2 SHAO Jin2 LIU Shuyi2 ZHANG Yan2

Cite this article:

KONG Dece1 YANG Tieyi2 SHAO Jin2 LIU Shuyi2 ZHANG Yan2. Changes of 25 hydroxy vitamin D3 in postmenopausal women between 50 and 60 years of age with fractures[J]. 中国医药导报, 2016, 13(3): 83-86.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2016/V13/I3/83

[参考文献]
[1] Khosla S，Atkinson EJ，Melton LJ，et al. Effects of age and estrogen status on serum parathyroid hormone levels and biochemical markers of bone turnover in women： a population based study [J]. J Clin Endocrinol Metab，1997， 82（5）：1522-1527.
[2] Burge R，Dawson-Hughes B，Solomon DH，et al. Incidence and economic burden of osteoporosis-related fractures in the United States，2005-2025 [J]. J Bone Miner Res，2007， 22（3）：465-475.
[3] Kanis JA，Johnell O. Requirements for DXA for the management of osteoporosis in Europe [J]. Osteoporos Int，2005，16（3）：229-238.
[4] Zhang R，Naughton DP. Vitamin D in health and disease： current perspectives[J]. Nutr J，2010，9：65.
[5] Szulc P. The role of bone turnover markers in monitoring treatment in postmenopausal osteoporosis [J]. Clinical Biochemistry，2012，45（12）：907-919.
[6] Chopin F，Biver E，Funck-Brentano T，et al. Prognostic interest of bone turnover markers in the management of postmenopausal osteoporosis [J]. Joint Bone Spine，2012，79（1）：26-31.
[7] Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases，cancers，and cardiovascular disease [J]. Am J Clin Nutr，2004，80（6 Suppl）：1678S-1688S.
[8] 王亮，马远征，李平生，等.绝经后骨质疏松合并2型糖尿病血清25羟维生素D水平研究[J].中国骨质疏松杂志，2011，17（9）：784-786.
[9] Felsenfeld AJ，Rodríguez M，Aguilera-Tejero E. Dynamics of parathyroid hormone secretion in health and secondary hyperparathyroidism [J]. Clin J Am Soc Nephrol，2007，2（6）：1283-1305.
[10] Vuceljic M，Ilic-Stojanovic O，Lazovic M，et al. Vitamin D and parathyroid hormone in relation to bone mineral density postmenopausal women [J]. Vojnosanit Pregl，2012，69（3）：243-248.
[11] 郭丽萍.活性维生素D3对糖尿病大鼠胰岛β细胞功能影响的研究[J].中国医药导报，2014，10（12）：27-29.
[12] Hwang JS，Tsai KS，Cheng YM，et al. Vitamin D status in non-supplemented postmenopausal Taiwanese women with osteoporosis and fragility fracture [J]. BMC Musculoskelet Disord，2014，15：257.
[13] 赵海洋，朱建民，张银网.上海地区中老年人维生素D与骨密度的相关性调查[J].中国骨质疏松杂志，2014， 20（3）：292-295.
[14] Vasikaran S，Eastell R，Bruyère O，et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment：a need for international reference standards [J]. Osteoporos Int，2011，22（2）：391-420.
[15] Funck-Brentano T，Biver E，Chopin F，et al. Clinical utility of serum bone turnover markers in postmenopausal osteoporosis therapy monitoring：a systematic review [J]. Semin Arthritis Rheum，2011，41（2）：157-169.
[16] Szulc P，Delmas PD. Biochemical markers of bone turnover：potential use in the investigation and management of postmenopausal osteoporosis [J]. Osteoporos Int，2008，19（12）：1683-1704.
[17] Biver E，Chopin F，Coiffier G，et al. Bone turnover markers for osteoporotic status assessment? A systematic review of their diagnosis value at baseline in osteoporosis [J]. Joint Bone Spine，2012，79（1）：20-25.
[18] Holroyd CR，Cooper C，Harvey NC. Vitamin D and the postmenopausal population [J]. Menopause Int，2011，17（3）：102-107.
[19] Khaw KT，Luben R，Wareham N. Serum 25-hydroxyvitamin D，mortality，and incident cardiovascular disease，respiratory disease，cancers，and fractures：a 13-y prospective population study [J]. Am J Clin Nutr，2014，100（5）：1361-1370.
[20] El Maghraoui A，Ouzzif Z，Mounach A，et al. Hypovitaminosis D and prevalent asymptomatic vertebral fractures in Moroccan postmenopausal women [J]. BMC Women's Health，2012，12：11.
[21] Tanaka S，Kuroda T，Yamazaki Y，et al. Serum 25-hydroxyvitamin D below 25 ng/mL is a risk factor for long bone fracture comparable to bone mineral density in Japanese postmenopausal women [J]. J Bone Miner Metab，2014，32（5）：514-523.
[22] Ebeling PR. Vitamin D and bone health：epidemiologic studies [J]. Bonekey Rep，2014，3：511.
[23] Rizzoli R，Boonen S，Brandi ML，et al. Vitamin D supplementation in elderly or postmenopausal women：a 2013 update of the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis （ESCEO）[J]. Curr Med Res Opin，2013，29（4）：305-313.
[24] Maier GS，Seeger JB，Horas K，et al. The prevalence of vitamin D deficiency in patients with vertebral fragility fractures [J]. Bone Joint J，2015，97-B（1）：89-93.
[25] 张荣伟，刘文静，张珣.维生素D对老龄小鼠脾部分切除术后认知功能的影响及其作用机制研究[J].中国医药导报，2014，11（31）：10-13.
[26] 闫景刚，段卫华.骨质疏松症治疗药物的研究进展[J].中国医药导报，2015，12（9）：34-37.
[27] Holick MF，Binkley NC，Bischoff-Ferrari HA，et al. Evaluation，treatment，and prevention of vitamin D deficiency：an endocrine society clinical practice guideline [J]. J Clin Endocrinol Metab，2011，96（7）：1911-1930.